Gene test could Fine-Tune transplant drug dosing

NCT ID NCT00552201

Completed Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested whether adjusting the first dose of the immunosuppressant drug tacrolimus based on a patient's CYP3A5 gene helps reach the right blood levels faster after kidney transplant. 280 kidney transplant recipients were randomly assigned to receive either a standard dose or a dose tailored to their genetic profile. The goal was to see if more patients in the gene-guided group achieved target tacrolimus levels within the first week.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tacrolimus
What this could lead to: If successful, this approach could help doctors personalize tacrolimus dosing for kidney transplant patients, potentially reducing the risk of rejection or side effects.
What could go wrong: This is a completed Phase 4 study with 280 participants, so results are available. However, the benefit may be limited to certain genetic groups, and the approach may not improve long-term outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

KIDNEY TRANSPLANTATION

Contacts and locations

Locations

CHU Angers

Angers, France
CHU Gabriel Montpied

Clermont-Ferrand, 63003, France
CHU Limoges - Hôpital Dupuytren

Limoges, 87042, France
CHU Poitiers- hôpital Jean Bernard

Poitiers, 86021, France
CHU Reims - Hôpital Maison Blanche

Reims, 51092, France
CHU Rennes - Hôpital Pontchaillou

Rennes, 35033, France
CHU Rouen - Hôpital de Bois-Guillaume

Bois-Guillaume, 76230, France
CHU Strasbourg - Hospices Civils

Strasbourg, 67091, France
CHU Tours - Hôpital Bretonneau

Tours, 37044, France
CHU de la côté de Nacre

Caen, 14033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.